1 Ashford D A, di Pietra J, Lingappa J,et al. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccineRB51[J]. Vaccine, 2004, 22(25~26): 3435~3439. 2 Bowden R A, Cloeckaert A, Zygmunt M S. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25 kDa major outer membrane protein of Brucella melitensis (OMP25) expressed in Escherichia coli[J]. J Med Micobiol,1998, 47(1): 39~48. 3 Cassataro J,Pasquevich K A,et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from OMP31 to the N-terminus of BLS induced a similar degree of protection against B.ovis than Rev.1 vaccination[J]. Vaccine, 2007, 25(22):4437~4446. 4 Cloeckaert A, Vizaino N, Paquet J Y. Major outer membrane protein of Brucella spp: Past, present, and future[J]. Veterinary Microbiology, 2002, 90(1~4):229~248. 5 Delpino M V, Estein S M, Fossati C A, et al. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice[J]. Vaccine, 2007, 25(37~38): 6721~6729. 6 Farshad S, Mehrebanpour M J, Namavari M M, et al. Production and characterization of monoclonal antibodies against Brucella abortus S(99) surface antigens[J]. Iran Biomed, 2002, 6(1): 7~12. 7 Nicoletti P. Vaccination against Brucella[J]. Adv Biotechnol Processes, 1990, 13:147~168. 8 Pasquevich K A, Garcia Samartino C, Coria L M, et al. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis[J].J Immunol,2010, 184(9):5200~5212. 9 Pasquevich K A, Estein S M, Garcia Samartino C, et al. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection[J]. Infect Immun, 2009, 77(1): 436~445. 10 Rajesh C. Brucellosis outbreak in an organized daifarm involving cows and in contact human beings[J]. Vet Bull, 2003, 73(9): 1250. 11 Reed S G, Bertholet S, Coler R N, et al. New horizons in adjuvants for vaccine development[J]. Trends Immunol, 2009, 30(1): 23~32. 12 Schurig G G, Sriranganathan N, Corbel M J. Brucellosis vaccines:Past, present and future[J]. Vet Microbiol, 2002, 90(1~4): 479~496. 13 Schijns V E. Immunological concepts of vaccine adjuvant activity[J]. Curr Opin Immunol, 2000, 12(4): 456~463. 14 Thakur S D, Kumar R, Thapliyal D C. Human brucellosis: Review of an under-diagnosed animal transmitted disease[J]. J Commun Dis, 2002, 34(4): 287~301. 15 Tibor A, Decelle B, Letesson J J. Outer membrane proteins Omp10, Omp16, and Omp19 of Brucella spp. are lipoproteins[J]. Infect Immun, 1999, 67(9): 4960~4962. 16 Winter A J, Rowe G E. Comparative immune responses to native cell envelope antigens and the hot sodium dodecylsulfate insoluble fraction (PG) of Brucella abortus in cattle and mice[J]. Vet Immunol Immunopathol,1988,18(2):149~163. |